Meticulous Research® Unveils Exclusive Report Forecasting Cancer/Tumor Profiling Market to Surpass $22.3 Billion by 2030

[Redding, California, March 12, 2024] - Meticulous Research®, a premier provider of market intelligence solutions, has released an authoritative report titled 'Cancer/Tumor Profiling Market,' foreseeing a remarkable market value surge to $22.3 billion by 2030, boasting an impressive Compound Annual Growth Rate (CAGR) of 20.9% from 2023 to 2030.

Download Free Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5630

Cancer/tumor profiling, an essential practice in both clinical and research realms, is set to witness unprecedented growth fueled by a multitude of factors. The escalating prevalence of cancer, augmented pharmaceutical Research and Development (R&D) expenditures, burgeoning targeted therapies, and the emergence of new actionable biomarkers collectively contribute to the market's upward trajectory. Additionally, substantial investments in cancer research, declining costs associated with Next-Generation Sequencing (NGS)-based profiling, and advancements in multi-omics tumor profiling further propel market expansion. However, the high capital requirements for NGS setups and prolonged turnaround times pose significant challenges to market growth.

Furthermore, the surge in personalized medicine development and the increasing adoption of targeted therapies present lucrative growth avenues. Nevertheless, obstacles such as the scarcity of genetic experts for result interpretation, lack of in-house tumor profiling technologies, and the prevalence of false biomarker discoveries loom as challenges for stakeholders in the cancer/tumor profiling market.

Browse in depth @ https://www.meticulousresearch.com/product/cancer-tumor-profiling-market-5630

Rise in R&D Investments by Pharmaceutical and Biopharmaceutical Companies for Biomarker Development to Drive Market Growth
The pharmaceutical and biopharmaceutical sectors continue to prioritize R&D endeavors, integral to drug and biomarker development processes. The industry's sustained growth is evidenced by heightened investments in R&D, aimed at meeting the escalating demand for innovation and groundbreaking medical discoveries. The significance of R&D is underscored by the surge in drug approvals, with the FDA approving a substantial number of novel drugs in recent years. Genome sequencing plays a pivotal role in enabling the development of precision medicines, further accentuating the demand for precise insights into cancer's molecular pathology. Elevated R&D investments in these sectors are anticipated to drive the demand for cancer/tumor profiling solutions.

Moreover, biomarkers play a pivotal role in translating non-clinical research outcomes into clinical practice, presenting significant growth opportunities for market players.

Key Segments and Market Dynamics
The cancer/tumor profiling market is segmented based on Biomarker Type, Technology, Cancer Type, Application, and End User. Notable findings include:
• Genetic biomarkers anticipated to dominate the market owing to their efficacy in treatment delivery and disease diagnosis.

• Next-generation sequencing (NGS) projected to hold the largest market share in technology segment due to its accuracy and declining sequencing costs.

• Breast cancer segment expected to lead in cancer type category, propelled by increasing cases and supportive government initiatives.

• Pharmaceutical & biopharmaceutical companies segment likely to witness significant growth, driven by declining sequencing costs and heightened demand for precision medicine.

Quick Buy - Cancer/Tumor Profiling Market - Global Opportunity Analysis and Industry Forecast (2023-2030), Research Report: https://www.meticulousresearch.com/Checkout/81920399

Some of the key players operating in the cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

This release was published on openPR.